Galecto regains Nasdaq minimum bid price compliance; matter closed

Damora Therapeutics, Inc.

Received Nasdaq Staff letter confirming compliance with Rule 5550(a)(2) based on bid price >= $1.00 from Aug 30 to Sep 13, 2024.
The deficiency notice is now closed; no further action required on this matter.
Shares continue trading on Nasdaq Capital Market under ticker GLTO.

item 8.01

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-107580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.